Conference Roundup

Potential benefit of teprotumumab dose reduction to be discussed at AAO 2022

  Adverse events, particularly hearing loss, in patients with thyroid eye disease (TED) treated with teprotumumab have been documented. In a session at AAO 2021, Sears CM, et al said adverse events in patients with TED treated with teprotumumab are common but most are mild to moderate in severity, although...